Form 8-K - Current report:
SEC Accession No. 0001159036-23-000020
Filing Date
2023-03-16
Accepted
2023-03-15 18:28:28
Documents
14
Period of Report
2023-03-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20230315.htm   iXBRL 8-K 36117
2 EX-99.1 ex991haloippressreleasefin.htm EX-99.1 15627
6 GRAPHIC image_0.jpg GRAPHIC 17587
  Complete submission text file 0001159036-23-000020.txt   208965

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20230315.xsd EX-101.SCH 1915
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20230315_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20230315_pre.xml EX-101.PRE 12520
8 EXTRACTED XBRL INSTANCE DOCUMENT halo-20230315_htm.xml XML 4103
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 23736575
SIC: 2836 Biological Products, (No Diagnostic Substances)